Beta-Amyloid (Aβ) Increases the Expression of NKCC1 in the Mouse Hippocampus.
Authors
Lam, PatriciaVinnakota, Chitra
Guzmán, Beatriz Calvo-Flores
Newland, Julia
Peppercorn, Katie
Tate, Warren P
Waldvogel, Henry J
Faull, Richard L M
Kwakowsky, Andrea
Issue Date
2022-04-10Keywords
Alzheimer’s diseaseGABA
KCC2
NKCC1
beta amyloid
bumetanide
Metadata
Show full item recordJournal
Molecules (Basel, Switzerland)DOI
10.3390/molecules27082440PubMed ID
35458638Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder with an increasing need for developing disease-modifying treatments as current therapies only provide marginal symptomatic relief. Recent evidence suggests the γ-aminobutyric acid (GABA) neurotransmitter system undergoes remodeling in AD, disrupting the excitatory/inhibitory (E/I) balance in the brain. Altered expression levels of K-Cl-2 (KCC2) and N-K-Cl-1 (NKCC1), which are cation-chloride cotransporters (CCCs), have been implicated in disrupting GABAergic activity by regulating GABAA receptor signaling polarity in several neurological disorders, but these have not yet been explored in AD. NKCC1 and KCC2 regulate intracellular chloride [Cl-]i by accumulating and extruding Cl-, respectively. Increased NKCC1 expression in mature neurons has been reported in these disease conditions, and bumetanide, an NKCC1 inhibitor, is suggested to show potential therapeutic benefits. This study used primary mouse hippocampal neurons to explore if KCC2 and NKCC1 expression levels are altered following beta-amyloid (Aβ1-42) treatment and the potential neuroprotective effects of bumetanide. KCC2 and NKCC1 expression levels were also examined in 18-months-old male C57BL/6 mice following bilateral hippocampal Aβ1-42 stereotaxic injection. No change in KCC2 and NKCC1 expression levels were observed in mouse hippocampal neurons treated with 1 nM Aβ1-42, but NKCC1 expression increased 30-days post-Aβ1-42-injection in the CA1 region of the mouse hippocampus. Primary mouse hippocampal cultures were treated with 1 nM Aβ1-42 alone or with various concentrations of bumetanide (1 µM, 10 µM, 100 µM, 1 mM) to investigate the effect of the drug on cell viability. Aβ1-42 produced 53.1 ± 1.4% cell death after 5 days, and the addition of bumetanide did not reduce this. However, the drug at all concentrations significantly reduced cell viability, suggesting bumetanide is highly neurotoxic. In summary, these results suggest that chronic exposure to Aβ1-42 alters the balance of KCC2 and NKCC1 expression in a region-and layer-specific manner in mouse hippocampal tissue; therefore, this process most likely contributes to altered hippocampal E/I balance in this model. Furthermore, bumetanide induces hippocampal neurotoxicity, thus questioning its suitability for AD therapy. Further investigations are required to examine the effects of Aβ1-42 on KCC2 and NKCC1 expression and whether targeting CCCs might offer a therapeutic approach for AD.Item Type
ArticleLanguage
enEISSN
1420-3049ae974a485f413a2113503eed53cd6c53
10.3390/molecules27082440
Scopus Count
Collections
Related articles
- Sevoflurane-Induced Dysregulation of Cation-Chloride Cotransporters NKCC1 and KCC2 in Neonatal Mouse Brain.
- Authors: Cabrera OH, Tesic V, Tat QL, Chastain S, Quillinan N, Jevtovic-Todorovic V
- Issue date: 2020 Jan
- Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders.
- Authors: Lam P, Newland J, Faull RLM, Kwakowsky A
- Issue date: 2023 Jan 31
- The chloride co-transporters, NKCC1 and KCC2, in experimental autoimmune encephalomyelitis (EAE).
- Authors: Yousuf MS, Zubkow K, Tenorio G, Kerr B
- Issue date: 2017 Mar 6
- Hippocampal chloride transporter KCC2 contributes to excitatory GABA dysregulation in the developmental rat model of schizophrenia.
- Authors: Atefimanash P, Pourhamzeh M, Susanabadi A, Arabi M, Jamali-Raeufy N, Mehrabi S
- Issue date: 2021 Dec
- Role of NKCC1 and KCC2 in Epilepsy: From Expression to Function.
- Authors: Liu R, Wang J, Liang S, Zhang G, Yang X
- Issue date: 2019